Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723257 | 0.84 | ALDH1A1 (0.40) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6407001 | 0.82 | GPR119 (0.47) | NR1H2RECQL | |
| SCHEMBL6407004 | 0.82 | GPR119 (0.47) | NR1H2RECQL | |
| SCHEMBL72535 | 0.81 | NR1H2 (0.51) | USP2SMN1; SMN2NR1H2RECQLDDB1 | |
| SCHEMBL13812216 | 0.81 | CHRM2 (0.54) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL4093465 | 0.79 | MEN1 (0.38) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL4093461 | 0.79 | MEN1 (0.38) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL13724256 | 0.79 | HRH1 (0.34) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL11344621 | 0.77 | USP2 (0.45) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL8242595 | 0.76 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203695-A1 | Compounds IV | GPR119, FABP4, LIPC | USP2 4000/4885SMN1; SMN2 4479/4885CHRM2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.